Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Source
No articles found.
Headquartered in Franklin, Tennessee, Acadia Healthcare was established in January...
Headquartered in Franklin, Tennessee, Acadia He...
The Kerluxe brand philosophy is to employ innovation synonymous with Swiss skincar...
The Kerluxe brand philosophy is to employ innov...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company i...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage...
Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission...
Teligent is a specialty generic pharmaceutical ...
PhaseBio is a clinical-stage biopharmaceutical company focused on the development ...
PhaseBio is a clinical-stage biopharmaceutical ...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Join the National Investor Network and get the latest information with your interests in mind.